Hydroxamic acids (therapeutics and mechanism): chemistry, acyl nitroso, nitroxyl, reactive oxygen species, and cell signaling

References

• Kovacic P, Somanathan R. Dermal toxicity and environmental contamination: electron transfer, reactive oxygen species, oxidative stress, cell signaling, and protection by antioxidants. Rev Environ Contam Toxicol 2010, 203, 119–138.
   PubMedGoogle Scholar
• Howard JA, Ilyashenko G, Sparkes HA, Whiting A. Development of new transition metal catalysts for the oxidation of a hydroxamic acid with in situ Diels-Alder trapping of the acyl nitroso derivative. Dalton Trans 2007, 21, 2108–2111.
   Google Scholar
• Cohen AD, Zeng BB, King SB, Toscano JP. Direct observation of an acyl nitroso species in solution by time-resolved IR spectrocopy. J Am Chem Soc 2003, 125, 1444–1445.
   Google Scholar
• King SB. N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr Top Med Chem 2005, 5, 665–673.
   PubMed Web of Science ®Google Scholar
• Fukuto JM, Jackson MI, Kaludercic N, Paolocci N. Examining nitroxyl in biological systems. Meth Enzymol 2008, 440, 411–431.
   Google Scholar
• Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, Hobbs AJ, Fukuto JM. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther 2007, 113, 442–458.
   Google Scholar
• Fukuto JM, Switzer CH, Miranda KM, Wink DA. Nitroxyl (HNO): chemistry, biochemistry, and pharmacology. Annu Rev Pharmacol Toxicol 2005, 45, 335–355.
   PubMed Web of Science ®Google Scholar
• Fukuto JM, Dutton AS, Houk KN. The chemistry and biology of nitroxyl (HNO): a chemically unique species with novel and important biological activity. Chembiochem 2005, 6, 612–619.
   Google Scholar
• Fukuto JM, Bartberger MD, Dutton AS, Paolocci N, Wink DA, Houk KN. The physiological chemistry and biological activity of nitroxyl (HNO): the neglected, misunderstood, and enigmatic nitrogen oxide. Chem Res Toxicol 2005, 18, 790–801.
   Google Scholar
• Flores-Santana W, Switzer C, Ridnour LA, Basudhar D, Mancardi D, Donzelli S, Thomas DD, Miranda KM, Fukuto JM, Wink DA. Comparing the chemical biology of NO and HNO. Arch Pharm Res 2009, 32, 1139–1153.
   Google Scholar
• Miranda KM, Ridnour L, Esprey M, Citrin D, Thomas D, Donzelli S, Wink DA, Katori T, Tocchetti CG, Ferlito M, Paolocci N, Fukuto JM. Comparison of the chemical biology of NO and HNO: An inorganic perspective. Prog Inorg Chem 2005, 54, 349–384.
   Google Scholar
• Miranda KM. The chemistry of nitroxyl (HNO) and implications in biology. Coord Chem Rev 2005, 249, 433–455.
   Web of Science ®Google Scholar
• Samuni Y, Flores-Santana W, Krishna MC, Mitchell JB, Wink DA. The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation. Free Radic Biol Med 2009, 47, 419–423.
   Google Scholar
• Lagercrantz C, Larsson T. Spin trapping of methyl radicals by the acyl nitroso compound Ph–C(= O)NO formed in the photochemical reaction between benzohydroxamic acid, dimethyl sulfoxide and hydrogen peroxide. An EPR study. Free Radic Res 1994, 20, 181–187.
   Web of Science ®Google Scholar
• Holder JW. Nitrobenzene carcinogenicity in animals and human hazard evaluation. Toxicol Ind Health 1999, 15, 445–457.
   PubMed Web of Science ®Google Scholar
• Hirota K, Itano HA, Vedvick TS. Oxidative degradation of haemoglobin by nitrosobenzene in the erythrocyte. Biochem J 1978, 174, 693–697.
   PubMedGoogle Scholar
• Niufar NN, Haycock FL, Wesemann JL, MacStay JA, Heasley VL, Kovacic P. Reduction potentials of conjugated aliphatic ketones, oximes, and imines: correlation with structure and bioactivity. Rev Mex Chem Soc 2002, 46, 307–312.
   Google Scholar
• Jacobs GP. Non-nitro radiation sensitizers. Int J Radiat Biol Relat Stud Phys Chem Med 1985, 49, 887–890.
   Google Scholar
• Russell GA. In “Radical Ions”. New York: Interscience 1968, 87–150.
   Google Scholar
• Kovacic P, Cooksy AL. Electron transfer as a potential cause of diacetyl toxicity in popcorn lung disease. Rev Environ Contam Toxicol 2010, 204, 133–148.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Somanathan R. Pulmonary toxicity and environmental contamination: radicals, electron transfer, and protection by antioxidants. Rev Environ Contam Toxicol 2009, 201, 41–69.
   PubMed Web of Science ®Google Scholar
• Kovacic P. Novel electrochemical approach to enhanced toxicity of 4-oxo-2-nonenal vs. 4-hydroxy-2-nonenal (role of imine): oxidative stress and therapeutic modalities. Med Hypotheses 2006, 67, 151–156.
   PubMedGoogle Scholar
• Kovacic P. Unifying mechanism for bacterial cell signalers (4,5-dihydroxy-2,3-pentanedione, lactones and oligopeptides): electron transfer and reactive oxygen species. Practical medical features. Med Hypotheses 2007, 69, 1105–1110.
   PubMedGoogle Scholar
• Portanova P, Russo T, Pellerito O, Calvaruso G, Giuliano M, Vento R, Tesoriere G. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 2008, 33, 325–331.
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001, 98, 10833–10838.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10, 3839–3852.
   PubMed Web of Science ®Google Scholar
• Tang DG, Li L, Zhu Z, Joshi B, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Krajewski S, Reed JC, Timar J, Porter AT. BMD188, A novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Pathol Oncol Res 1998, 4, 179–190.
   Google Scholar
• Jacintho JD, Kovacic P. Neurotransmission and neurotoxicity by nitric oxide, catecholamines, and glutamate: unifying themes of reactive oxygen species and electron transfer. Curr Med Chem 2003, 10, 2693–2703.
   PubMed Web of Science ®Google Scholar
• Choe CU, Lewerenz J, Fischer G, Uliasz TF, Espey MG, Hummel FC, King SB, Schwedhelm E, Böger RH, Gerloff C, Hewett SJ, Magnus T, Donzelli S. Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity. J Neurochem 2009, 110, 1766–1773.
   Google Scholar
• Wink DA, Feelisch M, Fukuto J, Chistodoulou D, Jourd’heuil D, Grisham MB, Vodovotz Y, Cook JA, Krishna M, DeGraff WG, Kim S, Gamson J, Mitchell JB. The cytotoxicity of nitroxyl: possible implication for the pathophysiological role of NO. Free Radic Biol Med 1999, 26, 1305–1313.
   Google Scholar
• Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004, 101, 18030–18035.
   PubMed Web of Science ®Google Scholar
• Cao Q, Yu C, Xue R, Hsueh W, Pan P, Chen Z, Wang S, McNutt M, Gu J. Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int J Biochem Cell Biol 2008, 40, 272–283.
   Google Scholar
• Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, Amin S, Weston A, Baird WM. Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. Bioorg Med Chem Lett 2005, 15, 1283–1287.
   PubMed Web of Science ®Google Scholar
• Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001, 115, 287–297.
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Müller C, Beck JF. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett 2006, 232, 148–160.
   Google Scholar
• Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Invest Ophthalmol Vis Sci 2009, 50, 4072–4079.
   Google Scholar
• Sangeetha SR, Singh N, Vender JR, Dhandapani KM. Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells. Endocrine 2009, 35, 389–396.
   Google Scholar
• Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 2009, 8, 1596–1605.
   Google Scholar
• Carlisi D, Lauricella M, D’Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009, 45, 2425–2438.
   PubMed Web of Science ®Google Scholar
• Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 2006, 281, 10508–10515.
   PubMed Web of Science ®Google Scholar
• Jiang X, Tsang YH, Yu Q. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. Int J Biochem Cell Biol 2007, 39, 1016–1025.
   Google Scholar
• Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007, 67, 5318–5327.
   PubMed Web of Science ®Google Scholar
• Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005, 16, 1125–1138.
   PubMed Web of Science ®Google Scholar
• Said TK, Moraes RC, Sinha R, Medina D. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res 2001, 3, 122–133.
   Google Scholar
• Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005, 125, 1045–1052.
   PubMed Web of Science ®Google Scholar
• Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003, 278, 12579–12589.
   PubMed Web of Science ®Google Scholar
• Forman HG, Cadenas E. Oxidative stress and signal transduction. In “Oxidative Stress and Signal Transduction.” Chapman and Hall, New York, 1997.
   Google Scholar
• Hancock GT. “Cell Signaling.” Oxford University Press, New York, 2000.
   Google Scholar
• Demple B. Oxidative stress and free radical signal transduction. In “Handbook of Cell Signaling.” Academic Press, New York, 2004, 191–195.
   Google Scholar
• Kovacic P, Pozos RS. Cell signaling (mechanism and reproductive toxicity): redox chains, radicals, electrons, relays, conduit, electrochemistry, and other medical implications. Birth Defects Res C Embryo Today 2006, 78, 333–344.
   PubMedGoogle Scholar
• Kovacic P. Protein electron transfer (mechanism and reproductive toxicity): iminium, hydrogen bonding, homoconjugation, amino acid side chains (redox and charged), and cell signaling. Birth Defects Res C Embryo Today 2007, 81, 51–64.
   PubMedGoogle Scholar
• Cerc G. Membrane electrostatics. Biochem Biophys Acta 1990, 1031, 311–382.
   Google Scholar
• Kovacic P. Simplifying the complexity of cell signaling in medicine and the life sciences: Radicals and electrochemistry. Med Hypotheses 2010, 74, 769–771.
   Google Scholar
• Kovacic P, Pozos RS. Bioelectronome. Integrated approach to receptor chemistry, radicals, electrochemistry, cell signaling, and physiological effects based on electron transfer. J Recept Signal Transduct Res 2007, 27, 261–294.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Pozos RS, Draskovich CD. Unifying electrostatic mechanism for receptor-ligand activity. J Recept Signal Transduct Res 2007, 27, 411–431.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Draskovich CD, Pozos RS. Unifying electrostatic mechanism for phosphates and sulfates in cell signaling. J Recept Signal Transduct Res 2007, 27, 433–443.
   PubMed Web of Science ®Google Scholar
• Kovacic P. Unifying electrostatic mechanism for metal cations in receptors and cell signaling. J Recept Signal Transduct Res 2008, 28, 153–161.
   PubMed Web of Science ®Google Scholar
• Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004, 10, 2289–2298.
   PubMed Web of Science ®Google Scholar
• Muri EM, Nieto MJ, Sindelar RD, Williamson JS. Hydroxamic acids as pharmacological agents. Curr Med Chem 2002, 9, 1631–1653.
   PubMed Web of Science ®Google Scholar
• Koncic MZ, Rajic Z, Petric N, Zorc B. Antioxidant activity of NSAID hydroxamic acids. Acta Pharm 2009, 59, 235–242.
   Google Scholar
• Kuzelová K, Pluskalová M, Brodská B, Otevrelová P, Elknerová K, Grebenová D, Hrkal Z. Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. J Cell Biochem 2010, 109, 184–195.
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009, 107, 600–608.
   PubMed Web of Science ®Google Scholar
• Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009, 1, 62–71.
   PubMedGoogle Scholar
• Wang L, Persons KS, Jamieson D, Flanagan JN, Hsu HH, Holick MF, Luo Z, Sakaki T, Urushino N, Faller DV, Chen TC. Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Anticancer Res 2008, 28, 2009–2013.
   PubMed Web of Science ®Google Scholar
• Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000, 60, 5165–5170.
   PubMed Web of Science ®Google Scholar
• Dalgard CL, Van Quill KR, O’Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 2008, 14, 3113–3123.
   PubMed Web of Science ®Google Scholar
• Zhuang ZG, Fei F, Chen Y, Jin W. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin 2008, 29, 1459–1466.
   Google Scholar
• Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat 2009, 117, 443–451.
   Google Scholar
• Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002, 99, 11700–11705.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006, 15, 187–191.
   PubMed Web of Science ®Google Scholar
• Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009, 24, 45–50.
   PubMed Web of Science ®Google Scholar
• Hölsken A, Eyüpoglu IY, Lueders M, Tränkle C, Dieckmann D, Buslei R, Hahnen E, Blümcke I, Siebzehnrübl FA. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 2006, 112, 205–215.
   PubMed Web of Science ®Google Scholar
• Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004, 9, 573–582.
   Google Scholar
• Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006, 12, 5570–5577.
   Google Scholar
• Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005, 11, 3958–3965.
   PubMed Web of Science ®Google Scholar
• Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006, 79, 259–270.
   PubMed Web of Science ®Google Scholar
• Jiang XX, Zhang QL, Chen XY, Wu WL, Shen ZX, Zhao WL. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009, 17, 1215–1219.
   Google Scholar
• Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin’s B-lymphoma cells apoptosis. Exp Hematol 2007, 35, 1801–1811.
   PubMed Web of Science ®Google Scholar
• Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, Nishimori T, Usui A, Miyazawa Y, Kamada T, Tsujii H, Matsubara H. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29, 4433–4438.
   PubMed Web of Science ®Google Scholar
• Tavares TS, Nanus D, Yang XJ, Gudas LJ. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 2008, 7, 1607–1618.
   PubMed Web of Science ®Google Scholar
• Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007, 110, 313–322.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008, 14, 6106–6115.
   PubMed Web of Science ®Google Scholar
• Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007, 105, 297–309.
   PubMed Web of Science ®Google Scholar
• Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 2008, 7, 1080–1090.
   PubMed Web of Science ®Google Scholar
• Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8, 1589–1595.
   PubMed Web of Science ®Google Scholar
• Seo SK, Jin HO, Lee HC, Woo SH, Kim ES, Yoo DH, Lee SJ, An S, Rhee CH, Hong SI, Choe TB, Park IC. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 2008, 73, 1005–1012.
   Google Scholar
• Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004, 128, 740–748.
   PubMed Web of Science ®Google Scholar
• Rundall BK, Denlinger CE, Jones DR. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 2005, 138, 360–367.
   PubMed Web of Science ®Google Scholar
• Kim JC, Shin ES, Kim CW, Roh SA, Cho DH, Na YS, Kim TW, Kim MB, Hyun YL, Ro S, Kim SY, Kim YS. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res 2009, 29, 3027–3034.
   Google Scholar
• Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007, 9, 440–451.
   Google Scholar
• Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006, 5, 1967–1974.
   PubMed Web of Science ®Google Scholar
• Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15, 2818–2828.
   PubMed Web of Science ®Google Scholar
• Yeh CC, Deng YT, Sha DY, Hsiao M, Kuo MY. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol Cancer Ther 2009, 8, 2718–2725.
   Google Scholar
• Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007, 6, 51–60.
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 2007, 6, 2976–2984.
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 2006, 6, 183.
   PubMed Web of Science ®Google Scholar
• Kovacic P. Fundamental, electron transfer mechanism by pyrylium-type ions for the anticancer drugs 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA). Curr Med Chem Anticancer Agents 2005, 5, 501–506.
   Google Scholar
• Kovacic P. Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications. Med Hypotheses 2007, 69, 510–516.
   PubMedGoogle Scholar
• Drahl C. Fixing function in cystic fibrosis. Chem Eng News 2009, 87, 35.
   Google Scholar
• Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR 3rd, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010, 6, 25–33.
   PubMed Web of Science ®Google Scholar
• Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009, 284, 6782–6789.
   PubMed Web of Science ®Google Scholar
• Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009, 25, 207–212.
   PubMed Web of Science ®Google Scholar
• Plewe MB, Butler SL, Dress KR, Hu Q, Johnson TW, Kuehler JE, Kuki A, Lam H, Liu W, Nowlin D, Peng Q, Rahavendran SV, Tanis SP, Tran KT, Wang H, Yang A, Zhang J. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors. J Med Chem 2009, 52, 7211–7219.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Somanathan R. Beneficial effects of antioxidants in relation to carcinogens, toxins and various illnesses. In “Frontiers in Antioxidant Research.” Nova Science, New York, 2006, 1–38.
   Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 1, 166.
   Google Scholar
• Kelly WK, Richon VM, O’Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9, 3578–3588.
   PubMed Web of Science ®Google Scholar
• Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7, 257–261.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23, 3923–3931.
   PubMed Web of Science ®Google Scholar
• Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49, 502–507.
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008, 26, 81–87.
   Google Scholar
• Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109, 31–39.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111, 1060–1066.
   PubMed Web of Science ®Google Scholar
• Rice CP, Park YB, Adam F, Abdul-Baki AA, Teasdale JR. Hydroxamic acid content and toxicity of rye at selected growth stages. J Chem Ecol 2005, 31, 1887–1905.
   PubMed Web of Science ®Google Scholar